Holen Sie sich die Stockscreener-App
985.08
0.80%
7.83
Handel nachbörslich:
984.50
-0.58
-0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Jim Cramer on Eli Lilly: “We’re Not Budging, We’d Buy More If It Really Got Hit” - Insider Monkey
Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPenKroger (NYSE:KR), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Boosts Chinese Manufacturing Investments - Advanced Manufacturing
Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program - 富途牛牛
Form Health Joins the Lilly Employer Connect Platform - Yahoo Finance Singapore
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Why this $6.3-billion money manager is buying Eli Lilly and selling a software firm - The Globe and Mail
Eli Lilly’s China Bet On Orforglipron Reshapes Obesity Drug Narrative - simplywall.st
Eli Lilly tops growth factor grades among S&P healthcare holdings (LLY:NYSE) - Seeking Alpha
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs? - sharewise.com
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 - Benzinga
Lilly Flags Safety Risk In Compounded GLP 1 - GuruFocus
Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives - GuruFocus
Jim Cramer Answered Questions About 13 Stocks: Eli Lilly, Meta, and More - Insider Monkey
Eli Lilly finds impurity in compounded tirzepatide - Pharmaceutical Technology
Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12 - Insurance Journal
Health risk alert as weight-loss jab manufacturer issues warning - The Independent
In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 - Fierce Pharma
Eli Lilly to invest $125m in Japan plant to boost supply of new drugs - Nikkei Asia
Eli Lilly (LLY) Warns Against Compounded Tirzepatide Products - GuruFocus
KLCM Advisors Inc. Sells 5,592 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Issues Warning on Safety Concerns of Compounded Tirzep - GuruFocus
Roberts Capital Advisors LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
ProQR Announces Year End 2025 Operating and Financial Results - GlobeNewswire Inc.
Health: Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Gulf Daily News
Eli Lilly Expands China Production for Weight Management Drugs | 2026News and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Eli Lilly and Company finds impurity in compounded diabetes and obesity drug knockoffs - Traders Union
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Reuters
Eli Lilly to invest USD 3bn in China - medwatch.com
PHARMARON Surges 12%+ After Reaching Production Co-op Agreement with Eli Lilly for Orforglipron - AASTOCKS.com
Pharmaron opens higher after reaching a production cooperation agreement for Orforglipron with Eli Lilly and Co. - 富途牛牛
Lilly to Invest $3 Billion in China to Boost Obesity Pill - Bloomberg.com
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia - The Manila Times
Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud - Law360
Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro - Insider Monkey
Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 - GuruFocus
As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 - Fierce Pharma
Lilly introduces direct-to-employer program for weight-loss drug - Indianapolis Business Journal
Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval - Pharmaceutical Technology
Eli Lilly (LLY) to Invest $3B in China for Weight Loss Drug Expa - GuruFocus
Eli Lilly's $3B China Investment for GLP-1 Drug Production | 2026News and StatisticsIndexBox - IndexBox - Market Intelligence Platform
After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there - Endpoints News
Eli Lilly (LLY) Submits Weight Loss Drug Application in China - GuruFocus
Wolfe bumps Eli Lilly target on oral obesity drug, cardiometabolic portfolio - Investing.com Nigeria
EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound - Benzinga
Hims & Hers taps ex-Eli Lilly PR chief to lead communications - medwatch.com
Kepler Cheuvreux Suisse SA Invests $3.10 Million in Eli Lilly and Company $LLY - MarketBeat
Bernstein Maintains Outperform on Eli Lilly (LLY) March 2026 - Meyka
Eli Lilly and Company $LLY Shares Sold by First Trust Advisors LP - MarketBeat
Financial Life Planners Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly to invest $3 billion in China, seeks approval for weight loss pill - Reuters
Eli Lilly invests USD 500m in South Korean life sciences - medwatch.com
Novo is losing India’s weight-loss market to Eli Lilly. How does it redeem itself? - The Ken
Samsung Biologics, Eli Lilly to launch startup hub in Korea - 매일경제
Hims Hires Ex-Lilly PR Chief as Its Weight-Loss Strategy Shifts - Bloomberg.com
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea - BioSpace
Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead - Fierce Biotech
Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports - Finviz
Bernstein reiterates Eli Lilly stock rating on GLP-1 expansion - Investing.com
Van ECK Associates Corp Purchases 6,260 Shares of Eli Lilly and Company $LLY - MarketBeat
FourThought Financial Partners LLC Increases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Samsung Biologics and Eli Lilly Launch Innovation Hub in Korea - Businesskorea
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Capital International Sarl Has $97.96 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Capital Group Private Client Services Inc. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):